Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 9/20 | 0.80 |
| ▸ | CTSB | P07858 | 7/20 | 0.80 |
| ▸ | CTSK | P43235 | 5/20 | 0.79 |
| ▸ | CTSS | P25774 | 5/20 | 0.79 |
| ▸ | CTSH | P09668 | 2/20 | 0.79 |
| ▸ | CTSC | P53634 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2310594 | 1.00 | CTSL (0.80) | CTSLCTSBCTSKCTSSCTSH | |
| SCHEMBL2310597 | 1.00 | CTSL (0.80) | CTSLCTSBCTSKCTSSCTSH | |
| SCHEMBL12433398 | 0.91 | CTSL (0.75) | CTSLCTSBCTSKCTSSCTSH | |
| SCHEMBL7349448 | 0.89 | CTSL (1.00) | CTSLCTSBCTSKCTSSCTSH | |
| SCHEMBL7349443 | 0.89 | CTSL (1.00) | CTSLCTSBCTSKCTSSCTSH | |
| SCHEMBL7355588 | 0.89 | CTSL (1.00) | CTSLCTSBCTSKCTSSCTSH | |
| SCHEMBL7355581 | 0.89 | CTSL (1.00) | CTSLCTSBCTSKCTSSCTSH | |
| SCHEMBL7349450 | 0.89 | CTSL (1.00) | CTSLCTSBCTSKCTSSCTSH | |
| SCHEMBL7352989 | 0.88 | CTSL (1.00) | CTSLCTSBCTSKCTSSCTSH | |
| SCHEMBL7352997 | 0.88 | CTSL (1.00) | CTSLCTSBCTSKCTSSCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618096-B2 | Prodrug compositions and methods for using the same in treating cancer and malaria | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110190291-A1 | Prodrug and Fluoregenic Compositions and Methods for Using the Same | REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190291-A1 | Prodrug and Fluoregenic Compositions and Methods for Using the Same | SLC19A1, SLC46A1, TFRC | CTSL 449/4885CTSB 467/4885CTSK 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.